A novel experimental drug for early Parkinson's disease (PD) yielded similar results as commercially available pramipexole extended-release (ER) but with significantly less daytime sleepiness, a new study shows.
The findings are the latest from a phase 3 trial of P2B001, an experimental drug that combines low-dose, ER formulations of pramipexole and rasagiline. Both drugs are already available at higher dosages. Extended-release rasagiline is not commercially available.
Side effects of Pramipexole and Madopar or the disease itself ??
Avoid medication - and suffer!
Should I start pramipexole???
New drug
yearly visit
